Related Experiment Video
Updated: May 21, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Scoping review of the use of multimorbidity variables in cardiovascular disease risk prediction
Emma Church1, Katrina Poppe2, Susan Wells2
1University of Auckland, Auckland, New Zealand. emma.church@auckland.ac.nz.
Insights
Cardiovascular disease (CVD) risk models need multimorbidity measures. Current models are less accurate for those with multiple conditions, highlighting a need for improved risk prediction and management strategies.
Area of Science:
- Cardiology
- Epidemiology
- Public Health
Background:
- Cardiovascular disease (CVD) is a leading global cause of death.
- Existing CVD risk prediction models show reduced accuracy in adults with multimorbidity.
- Single-disease paradigms may be inadequate for multimorbid individuals at risk of both CVD and non-CVD mortality.
Purpose of the Study:
- To conduct a scoping review of evidence on incorporating multimorbidity measures into CVD risk models.
- To assess the methodologies used for including multimorbidity in CVD risk prediction.
- To identify evidence gaps in the literature regarding multimorbidity and CVD risk.
Main Methods:
- Literature search from January 2012 to September 2022 in MEDLINE, Embase, and Cochrane databases.
- Utilized the Arksey and O'Malley framework for the scoping review.
- Adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines.
Main Results:
- Fourteen studies included multimorbidity variables in multivariable prognostic CVD models.
- Only four studies assessed the added benefit of multimorbidity variables in CVD risk models.
- Significant evidence gaps exist, including limited literature, underrepresentation of ethnic subpopulations, and lack of comparative assessment of multimorbidity indices.
Conclusions:
- Few studies have evaluated multimorbidity indices in primary and secondary CVD prevention cohorts.
- Further research is essential to determine the incremental value of multimorbidity indices in CVD risk prediction.
- Improved risk stratification and management strategies are needed for individuals with multimorbidity.
Background:
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality globally. Many countries use pooled cohort equations or similar risk prediction models to assess atherosclerotic CVD risk to guide preventive measures. There is evidence that clinical CVD risk prediction equations are less accurate for adults with higher levels of multimorbidity (the co-occurrence of multiple long-term conditions). Operating within a single disease paradigm may not be appropriate for adults with multimorbidity who may be at higher risk of both CVD and non-CVD death. This scoping review was conducted to gather evidence on the inclusion of multimorbidity measures in CVD risk models to assess their methodology and identify evidence gaps in the literature.
Methods:
The review covers literature from 1 January 2012 to 23 September 2022, using the Arksey and O'Malley framework. We searched MEDLINE, Embase, and Cochrane databases published during this period and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) reporting guidelines.
Results:
This review identified fourteen studies reporting multivariable prognostic CVD models that included a multimorbidity variable. Of these, four studies specifically looked at the added benefit of a multimorbidity variable in a CVD risk model. Only one of these studies was conducted in a primary prevention cohort (i.e., people were free of CVD at baseline). This scoping review revealed several primary evidence gaps, notably the limited literature on the topic, the model performance in ethnic subpopulations, and the comparative assessment of alternative multimorbidity variables beyond the Charlson Comorbidity Index.
Conclusions:
Few studies have assessed the impact of incorporating multimorbidity indices in primary and secondary prevention cohorts. Future research is needed to evaluate the incremental value of multimorbidity indices in cardiovascular disease risk prediction models to inform risk stratification and management strategies in people with multimorbidity.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
07:51Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Related Concept Videos
Factors Affecting Illness
For instance, risk factors are connected to illness,...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Bias in Epidemiological Studies
Classification of Illness
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...